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ABSTRACT 
Eleven lactating women were inadvertently vaccinated with 17DD yellow fever vaccine 
in a small city of Sao Paulo State, Brazil. Their infants were being exclusively breast-fed and 
the breastfeeding was interrupted for 10 days. Serum and breastmilk were collected from 
the vaccinated mothers and tested for the presence of genomic RNA of the vaccine strain 
8, 10 and 15 days after vaccination. Viral RNA was not detected in any of the serum and 
human milk samples tested and the infants remained asymptomatic. Our result strengthens 
the effectineness of stopping breastfeeding for 10 days after the inadvertent yellow fever 
vaccination of lactating women.
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INTRODUCTION
On April 17 2017, 11 women had scheduled measles, mumps, and rubella 
(MMR) vaccination in the first postpartum visit in a primary health care unit in 
Angatuba, a small city with approximately 24,000 inhabitants in Sao Paulo State, 
Brazil. However, the 11 women were inadvertently vaccinated with the 17DD 
yellow fever (YF) vaccine (Fiocruz, Brazil). The vaccines were from the same batch 
(167VFC037Z). All of their infants were exclusively breast-fed. The women had 
not been vaccinated for YF previously. 
Yellow fever vaccine is a live, attenuated virus preparation made from various 
strains of the 17D YF virus lineage. In Brazil, YF vaccine from the 17DD strain 
is produced by Bio-Manguinhos, a public sector vaccine manufacturer from the 
Oswaldo Cruz Foundation of the Brazilian Ministry of Health. YF vaccination is 
currently recommended in the entire Brazilian territory. 
A YF outbreak was reaching Sao Paulo State in April 2017. The transmission 
area was close to the border with Minas Gerais State, in the Northeast of Sao Paulo 
State, more than 200 Km from Angatuba. Despite being outside the transmission 
risk area at that time, YF vaccination is recommended in Angatuba since the 2009 
YF outbreak in the Middle West of Sao Paulo State1. 
The vaccination error was promptly reported to the health department of 
Angatuba and to the adverse event following immunization surveillance system. 
The Epidemiological Surveillance Center of Sao Paulo State (CVE) assisted the 
health department of Angatuba. The objectives were to avoid and to monitor the 
transmission of YF vaccine virus through breastfeeding and to investigate the 
presence of the virus in human milk.
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MATERIALS AND METHODS
The public health actions that were taken are: 1) 
Breastfeeding was immediately interrupted for 10 days and 
a special formula and appropriate baby bottle were made 
available to the mothers; 2) The babies who had breastfed 
after the mother had been vaccinated were followed by a 
pediatrician in a primary health care unit for 28 days for 
medical assistance if any sign or symptom appeared and 
a report of their health conditions was sent to the health 
department of Angatuba; 3) Serum and breastmilk were 
collected from the vaccinated mothers and sent to the 
Instituto Adolfo Lutz, an arbovirus reference laboratory 
in Sao Paulo State, Brazil, in order to test for the presence 
of genomic RNA of the vaccine virus strain and specific 
immunoglobulin M (IgM) antibodies.
The first serum and milk samples from all women were 
collected 8 days after vaccination (April 25), followed by 
collection 10 and 15 days after vaccination (April 27 and 
May 2, respectively). No infant serum was collected for 
YF virus testing.
Viral RNA was extracted from 140 µL of serum using 
a QIAmp® viral RNA minikit (Qiagen, Hilden, Germany) 
and from 500µL of milk with a PureLink® Viral RNA/DNA 
minikit (Invitrogen, Thermo Fisher Scientific, Waltham, 
USA), according to the manufacturer’s instructions. Viral 
genome was tested by real time reverse transcription 
polymerase chain reaction (RT-qPCR) protocol2. The Center 
for Diseases Control and Prevention (CDC/USA) protocol 
of MAC-ELISA was used for detecting IgM antibodies. 
The present investigation was the official response to 
a public health crisis, thus not requiring an ethical council 
approval.
RESULTS
Table 1 shows the results of the tests performed. Viral 
RNA was not detected in any of the serum and breast milk 
samples tested. On day 8 after vaccination 10 women had 
a breastmilk sample tested and none had a positive RNA 
amplification test, resulting in a 0% detection rate with a 
95% confidence interval (0 to 29,09). Only one of the 11 
women had a positive result for specific YFV-IgM detection. 
No symptoms were reported among the infants. 
DISCUSSION
Yellow fever virus, either the wild-type or the vaccinal 
one, have not been isolated from or detected in human 
breast milk3. However, there are previous reports of YF 
vaccine virus transmission through breastfeeding4-6. Both 
cases were infants who developed meningoencephalitis 
after their mothers had been vaccinated for YF during a 
postpartum visit. Yellow fever-specific IgM antibodies were 
present in the infant’s serum and in the cerebrospinal fluid 
in the two cases4-6. 
The World Health Organization (WHO) recommends 
that a risk-benefit assessment should be undertaken for all 
lactating women7. In areas where YF is endemic, or during 
outbreaks, the benefits of YF vaccination are likely to far 
Table 1 - RT-qPCR results in human milk and serum samples and IgM results in serum samples of mothers inadvertently vaccinated 
for yellow fever, stratified by period (days) after vaccination. Angatuba, April 2017.
Mothers
8th day 10th day 15th day
Milk Blood Milk Blood Milk Blood
RT-qPCR IgM RT-qPCR RT-Qpcr IgM RT-qPCR RT-qPCR IgM RT-qPCR
1 N N N N N N N N N
2 N N N N N N - N N
3 N N N N N N N N N
4 N N N N N N N N N
5 N N N N N N N N N
6 N N N N N N N N N
7 N N N N N N N N N
8 N N N N N N N N N
9 N N N N N N N N N
10 ND N ND N N N ND N N
11 N P N ND ND ND ND ND ND
N = negative; P = positive; ND = not done.
Rev Inst Med Trop São Paulo. 2020;62:e33
The search for yellow fever virus vaccine in breast milk of inadvertently vaccinated women in Brazil
Page 3 of 4
outweigh the risks of a potential transmission of the vaccine 
virus to the infant. Vaccination is also recommended, if 
indicated, to pregnant or breastfeeding women travelling 
to endemic areas when the travel cannot be avoided or 
postponed7. According to the Brazilian Ministry of Health 
(MoH), the vaccination of mothers breastfeeding children 
under the age of 6 months should be avoided or postponed 
until the child reaches 6 months of age6. If it is not possible 
to postpone the vaccination, the mother can store breast milk 
before the vaccination, to be offered to the infant during the 
period in which breastfeeding will be interrupted8.
Before 2016, the MoH recommended 15 days of 
breastfeeding interruption after YF vaccination8. During 
the 2016 - 2019 YF outbreak, the recommendation changed 
to 10 days of breastfeeding interruption9. In this study the 
17DD virus was not detected in human milk eight days 
after YF vaccination in 11 women and none of the infants 
developed any symptoms.
This study has some clear limitations, the small sample 
size does not allow us to rule out the occurrence of rare 
adverse events. It is also theoretically possible that, if the 
virus was present in the breast milk in very low quantities, 
the RNA amplification test could come out negative and 
transmission could still occur. No samples were collected 
from the infants, which could have helped to rule out an 
asymptomatic transmission of the yellow fever vaccine 
virus. Nonetheless, the fact that no adverse effects were 
reported in infants is reassuring.
Studies based on surveillance data showed that the 
wrong vaccine administered is the most commonly reported 
vaccination error10,11. The vaccination error in Angatuba was 
classified as an accidental and isolated event. YF vaccine 
and MMR vaccine have multiple dose presentation and 
they have the same producer (Bio-Manguinhos), which 
could facilitate the confusion. However, the color of the 
bottle cap and the label are different. The current high 
number of different vaccines available in the Brazilian 
immunization schedule in Brazil demands well prepared 
health professionals. Vaccination errors are serious events 
because they may harm patients and also cause a negative 
impact on the population’s confidence on vaccination, 
resulting in reduction of the immunization coverage10.
Despite these limitations, our results strengthens the 
eeffectiveness of the Brazilian MoH recommendations 
to interrupt breastfeeding for 10 days after vaccination. 
It should also be considered that strategies to minimize 
breastfeeding interruptions are desirable considering its 
importance for the infants’ development12,13. Further studies 
are required to rule out the occurrence of rare adverse events 
in this population.
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